Nektar, BMS pair graduates with honors across several tumor types

Nektar Therapeutics Inc.'s vice president of clinical development, Mary Tagliaferri, told BioWorld that the compelling objective response rate and impressive DCR with NKTR-214 when paired with Opdivo likely put the program in line for accelerated approval.